These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2466172)

  • 21. Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.
    Krusell LR; Christensen CK; Lederballe Pedersen O
    Eur J Clin Pharmacol; 1986; 30(6):641-7. PubMed ID: 2876898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
    Carlsen JE; Kardel T; Hilden T; Tangø M; Trap-Jensen J
    Clin Physiol; 1981 Aug; 1(4):375-84. PubMed ID: 7199409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of [14C]pinacidil in humans.
    DeLong AF; Oldham SW; DeSante KA; Nell G; Henry DP
    J Pharm Sci; 1988 Feb; 77(2):153-6. PubMed ID: 3361430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of effect of pinacidil on theophylline pharmacokinetics and metabolism in man.
    Nielsen-Kudsk JE; Nielsen CB; Mellemkjaer S; Siggaard C
    Pharmacol Toxicol; 1990 Aug; 67(2):156-8. PubMed ID: 2255669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N"-Cyano-N-4-pyridyl-N'-1,2,2-trimethyl-propylguanidine, a new vasodilating agent: acute effect of blood pressure and pharmacokinetics in hypertensive patients.
    Kardel T; Hilden T; Carlsen J; Trap-Jensen J
    J Cardiovasc Pharmacol; 1981; 3(5):1002-7. PubMed ID: 6168845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
    Ward JW; McBurney A; Farrow PR; Sharp P
    Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
    Petersen HJ; Nielsen CK; Arrigoni-Martelli E
    J Med Chem; 1978 Aug; 21(8):773-81. PubMed ID: 691003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity.
    Smallwood JK; Steinberg MI
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):102-9. PubMed ID: 2459526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
    Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
    Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic modeling between pinacidil or pinacidil-N-oxide plasma levels and systemic and regional hemodynamic effects in healthy volunteers.
    Bellissant E; Chau NP; Thuillez C; Giudicelli JF
    Fundam Clin Pharmacol; 1994; 8(5):437-45. PubMed ID: 7875638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and structure-activity relationships of thienylcyanoguanidine derivatives as potassium channel openers.
    Yoshiizumi K; Ikeda S; Nishimura N; Yoshino K
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2005-10. PubMed ID: 9433770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary evaluation of pinacidil in hypertension.
    Ramsay LE; Freestone S
    Br J Clin Pharmacol; 1983 Sep; 16(3):336-8. PubMed ID: 6626426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism of the new antihypertensive agent pinacidil in rat, dog and man.
    Eilertsen E; Magnussen MP; Petersen HJ; Rastrup-Andersen N; Sørensen H; Arrigoni-Martelli E
    Xenobiotica; 1982 Mar; 12(3):187-96. PubMed ID: 7113255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
    Takemoto T; Eda M; Okada T; Sakashita H; Matzno S; Gohda M; Ebisu H; Nakamura N; Fukaya C; Hihara M
    J Med Chem; 1994 Jan; 37(1):18-25. PubMed ID: 8289193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of pinacidil in hypertensive dialysis patients.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):375-80. PubMed ID: 4029243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment.
    Cinquegrani MP; Liang CS
    Clin Exp Hypertens A; 1988; 10(3):411-31. PubMed ID: 3359658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
    D'Arcy V; Laher M; McCoy D; Sullivan P; Walsh CH; Hickey MP
    Eur J Clin Pharmacol; 1985; 28(3):347-9. PubMed ID: 4007040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.